Diminished quality of life (QOL) is a common feature of epilepsy. It is generally more severe among patients with poor seizure control but prevalent, to a clinically significant degree, even among those whose seizures are well controlled. People with epilepsy frequently report diminished socialization, negative self image, feelings of stigmatization, reduced earnings potential, and diminished hope and ambition. Problems with antiepileptic drug (AED) therapy are common, and AED therapy is recognized as an important determinant of health-related quality of life (HRQOL). A clinically efficient psychometric instrument is needed to measure its impact. The Side Effect and Life Satisfaction (SEALS) inventory is a 38-item, patient-completed questionnaire designed to measure satisfaction with AED therapy. We tested its construct validity in comparison with three widely used psychometric instruments of similar design, the Profile of Mood States (POMS), the Hospital Anxiety and Depression (HAD) scale, and the Medical Outcomes Study-Cognitive Functioning (MOS-COG) scale.
INTRODUCTION
There is ample evidence that many people with epilepsy also suffer a clinically significant deficit in health-related quality of life (HRQOL) [1] [2] [3] , both in terms of symptoms resulting directly from the condition, and loss of psychosocial functioning consequent upon these symptoms. The psychosocial injury of epilepsy is more severe among patients with poor seizure control, but prevalent, to a clinically significant degree, even among patients whose seizures are reasonably well controlled 1, 2 . Baker et al. 1 surveyed 5211 members of epilepsy support groups and outpatient clinics in 15 European countries-a study population acknowledged to contain a disproportionately high number of people with epilepsy of greater than average severity. Many respondents said epilepsy had negatively affected their plans and ambitions (47%), social life (41%), and feelings about themselves (40%). Thirty-eight percent said epilepsy had diminished their ability to work and their standard of living. In a smaller survey 2 of 696 patients selected by protocol (≥1 seizure in the past 2 years or seizure-free on continuing AED therapy) from the records of 31 UK general practitioners, 44% of patients answered 'a lot' or 'some' when asked if epilepsy had limited the kind of work they could do. Other aspects of life reported to be similarly affected included relationships with friends (37%), feelings of self (37%), plans and ambitions (35%), social activities (32%), and ability to work (29%).
Aside from its anticonvulsant effects, AED therapy is an important medical factor influencing HRQOL. Not only is drug therapy a daily reminder to the patient of his or her condition, it can also exert a strong negative influence in the form of unwanted side effects, particularly cognitive and neurological impairment 4 . Baker et al. 1 reported that 88% of 96% of 5211 re-spondents on AEDs experienced at least one neurological AED side effect in the month prior to the survey. The most common were tiredness (58%), memory problems (50%), difficulty concentrating (48%), sleepiness (45%), difficulty thinking clearly (40%), and nervousness and agitation (36%). Forty-four percent said they worried 'a lot' or 'some' about the possible side effects of AED therapy, and 31% had changed AEDs at least once in the past year because of side effects. Patients in the UK-generalists study 2 reported AED side effects 'always a problem' or 'sometimes a problem' as follows: tiredness (41%), memory problems (33%), difficulty concentrating (30%), sleepiness (28%), nervousness/agitation and headache (26%, each), depression (25%), disturbed sleep (24%), restlessness (21%), and feelings of aggression (19%).
To better understand the component role of AED therapy in HRQOL and to determine whether the psychosocial injury of epilepsy can be ameliorated without compromising the primary therapeutic goal of optimum seizure control, researchers and practitioners need a reliable, validated, clinically efficient psychometric instrument to measure patient satisfaction with AED therapy. In 1982, Brown and Tomlinson 5 described the development of a patient-completed questionnaire to assess the psychosocial effects of AED therapy, termed the Side Effect and Life Satisfaction (SEALS) inventory, using a patient population to generate key symptoms. The goal was to construct an instrument to distinguish not just drug effects from disease effects, but also to distinguish the psychosocial effects of one antiepileptic drug from those of another in comparative clinical trials. To be useful in such studies, the questionnaire had to be practical for repeated use, i.e. simple to understand and not excessively time consuming. It also had to be sensitive to small changes in the patient's HRQOL over time. The final version comprised 50 questions scored on a fourpoint Likert scale and grouped by five subscales or 'factors': fatigue; satisfaction; interpersonal relations; mood and irritability; and general cognitive difficulties.
Gillham et al. 6 studied and modified the BrownTomlinson SEALS to produce the refining of the five factors and reducing the number of questions to 38, using principal components analysis. The twelve discarded questions did not load significantly on any one factor; they tended to be items confounded by factors not necessarily related to the patient's epilepsy, such as marital status, or personal preferences. Gillham and associates also showed that the five SEALS factors were sensitive to differences between treatment groups and to changes in treatment, findings that suggest the SEALS inventory would be useful to assess patient satisfaction with anticonvulsant therapy.
The present study was undertaken to test the construct validity of the SEALS inventory, using for comparison three well-validated instruments similar to the SEALS inventory or one of its five factors: the Profile of Mood States (POMS) 7 , the Hospital Anxiety and Depression (HAD) scale 8 , and the Medical Outcomes Study-Cognitive Functioning (MOS-COG) scale 9 .
MATERIALS AND METHODS
Approval from the local Ethics Committee was sought and obtained at two sites; (Glasgow and Dundee), at the third, (Liverpool), completion of the questionnaires was deemed a normal part of clinical practice, obviating Committee approval.
Patients and data collection
Enrollment was open to men and women 18 years of age or older with epilepsy diagnosed by a consultant neurologist. Newly diagnosed patients and patients still undergoing investigation were excluded, as were those who lacked the ability to read, comprehend, and complete the SEALS inventory and comparative instruments without assistance (12 patients). Demographic data and information on disease characteristics were gathered by clinic personnel through direct interview and from clinic records. Consecutively presenting patients at three clinics were invited to participate in the study. Each prospective patient received written and oral instruction regarding the nature and purpose of the study. Consent was inferred from the informed patient's willingness to participate, and was virtually 100% amongst those patients who did not have further appointments imposing time constraints. Refusal to participate in one centre (Liverpool n = 100) was not recorded, but in the other two centres was less than 1%. Participation entailed completing the SEALS inventory and the three comparative instruments. Written and oral instructions for each instrument were provided, but once the patient began, no further assistance was available except staff's encouragement to carefully reread the written instructions. Questionnaires were completed in the clinic, in a side room, before the patient's routine appointment. There was no time limit, implied or prescribed, for completion of the SEALS inventory or the other instruments, and the average time to complete was 45 minutes.
Psychometric instruments and validation strategy
The SEALS inventory contains 38 questions related to the patient's feelings and behaviour over the past week, e.g. 'Have you felt enthusiastic about doing things?' 'Have you been irritable with people?'. The questions are grouped into five subscales based on the results of factor analysis, termed: Worry, Temper, Cognition, Dysphoria, and Tiredness. Each question is answered on a four-point Likert scale (0 = never, 1 = occasionally, 2 = sometimes, 3 = many times). Answers are summed to provide a score for each factor, and factor scores are totaled for an overall SEALS score. The POMS scale 7 measures six mood states: tension-anxiety, depression-rejection, anger-hostility, vigour-activity, fatigue-inertia, and confusionbewilderment. Sixty-five adjectives (e.g. tense, lively, nervous, worthless) are rated on a five-point Likert scale (0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, 4 = extremely). Patients are asked to relate each adjective to their personal sense of well-being over the past week.
The HAD scale 8 consists of two subscales (depression and anxiety) comprising 14 statements about the patient's feelings over the past week, e.g. 'I feel tense or wound up.' Patients choose one of four possible responses to which point values have been assigned, e.g. 'not at all' (no points), 'occasionally' (1 point), 'a lot of the time' (2 points), and 'most of the time' (3 points). Items are summed by subscale to provide two scores: one for depression and one for anxiety.
The MOS-COG scale 9 uses six questions scored on a six-point Likert scale to provide a general measure of the patient's cognitive function from his or her point of view, e.g. 'Did you have difficulty reasoning and solving problems, for example, making plans, making decisions, learning new things?' (1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, and 6 = none of the time). Answers are summed to provide a single score reflecting such concepts as confusion, forgetfulness, slowed reaction, difficulty reasoning, trouble paying attention, and difficulty with activities that require mental concentration.
Total SEALS score was validated against total POMS score. The validation strategy for individual factor scores is shown in Table 1 .
RESULTS
Three hundred and seven volunteers contributed usable data to this study. Table 2 summarizes their demographic and disease characteristics. Questionnaires with less than 80% of the items answered according to the protocol were not used in the final analysis, and data from 15 patients were thus excluded, for a compliance rate of 95% (307/322).
A matrix of Pearson's correlations was produced for the SEALS inventory and the comparative instruments. Correlations between measures had to be greater than 0.3 to be considered evidence of the convergent validity of the SEALS inventory. A statistically significant correlation was found for each comparison (Table 3) .
DISCUSSION
The SEALS inventory was originally designed to measure the effects of anticonvulsant therapy on psychosocial functioning. Detailed accounts of the method by which it was developed are given in Brown and Tomlinson 5 and Gillham et al. 6 , and will not be reiterated here. The earliest unpublished versions may be considered somewhat diffuse, with some degree of arbitrariness in item selection, but subsequent studies 5, 6 have refined it and in its present form, the SEALS inventory demonstrates the requisite qualities of validity, reliability, and responsiveness to be useful in clinical research and in the practical setting. Kane et al. 10 used data from three clinical trials of lamotrigine (n = 380) to evaluate the reliability of the SEALS inventory. Scale structure was evaluated across each study by calculating item-scale correlations for each item, using Cronbach's coefficient alpha. Internal consistency was also measured using Cronbach's coefficient alpha; a value greater than 0.7 is considered sufficient evidence of internal consistency 11 . Ninety-one percent of the correlations (104 of 114) matched their expected subscale, and Cronbach's alpha was >0.7 for the temper, cognition, dysphoria, and tiredness subscales. For the worry subscale, internal consistency varied from 0.65 to 0.70, depending on the study.
Responsiveness of the SEALS inventory has been demonstrated in three clinical studies comparing lamotrigine (LTG) with carbamazepine (CBZ), phenytoin (PHT), and valproate (VPA). The SEALS inventory was used in each study to monitor drug effects on HRQOL. In a 48-week randomized, double- blind comparison of LTG and CBZ 12 , SEALS scores showed significant improvement from baseline among LTG patients. The CBZ group showed no improvement. This finding is consistent with the LTG group's higher 48-week completion rate of 65% vs. 51%. In a 48-week randomized, double-blind comparison of LTG and PHT 13 , SEALS scores improved in the LTG group but worsened slightly in the PHT group; the final difference was statistically significant, again mir- For each language, two independent translations of the SEALS inventory were completed by native speakers of the target language who were also fluent in the source language (UK English). Those 'forward' translations were reconciled into a single version and then translated back into UK English by a native speaker of UK English who was fluent in the target language. The 'back' translation was then compared and reconciled with the original SEALS inventory. For each target language, five native speakers with epilepsy were enlisted to test the clarity, appropriateness, and acceptability of the translated SEALS inventory, and at an international harmonization meeting, the nine translations were compared with each other and with the original to ensure the conceptual equivalence of all versions. Missing data are the bane of quality-of-life research, and we are pleased to note that 95% of the patients in the present study returned questionnaires with ≥80% of the requested information supplied, with less than 1% refusing to participate in the two centres where such data was recorded. The situation in which the questionnaires were completed, in a clinic, with personnel known to the patient making the request, may have somewhat artificially raised compliance rate. The relatively short length of 38 questions and simple design of the SEALS inventory, however, probably confers an advantage of simplicity over instruments such as like the Liverpool HRQOL Battery 16 , the Epilepsy Surgery Inventory 17 , and QOLIE-89 18 in that the SEALS response choices are uniform throughout the inventory and each item is graded on the same fourpoint Likert scale.
The sample used for the study is highly selected. All patients were attending tertiary centres, and so there was a bias towards patients with poor seizure control. Those with learning disability were not able to take part if the demands of completing the questionnaires were beyond them. Thus, two very significant groups amongst people with epilepsy, those with good seizure control, and those with learning disability, were underrepresented. If the purpose of the study had been to draw any conclusions about epilepsy or its treatment, then clearly there would be a major flaw in the methodology, but since the purpose was to validate the SEALS against other measures, the selection bias is of less significance. There is a theoretical possibility that at the lower ends of scoring (better HRQOL), not well represented in this sample, the correlations between the instruments would be different; it might be supposed that they would be less because patient responses might be more influenced by non-illness related factors, and therefore subject to greater individual differences. If the intention was to use the SEALS amongst a population of non-clinic attenders, presumably bettered controlled with fewer AED side effects, then a further validation study with a sample from that population might be desirable. It is envisaged, however, that the SEALS should be used to monitor patients attending the same kind of clinics as those in this study, where HRQOL is a major issue. It is most important, therefore, that the instrument should be validated in that population.
CONCLUSION
The present study affirms the construct validity of the SEALS inventory, giving researchers and practitioners an effective and efficient tool to study and monitor the effect of AED therapy on HRQOL. The SEALS inventory is easy to administer and easy to complete. Clinical studies prove it is sensitive to small changes in HRQOL and can distinguish between different anticonvulsant drugs. The recent completion of nine crosscultural translations from the UK English original increases the potential usefulness of the SEALS in multinational trials of AED therapy as well as the dayto-day management of epilepsy around the world.
